CF PharmTech, Inc. Achieves Major Milestone: Inclusion in Shanghai and Shenzhen-Hong Kong Stock Connect

Key Highlights from the Announcement

• CF PharmTech, Inc. (“the Company”) has been officially included in the list of eligible securities for the Hong Kong Stock Connect under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect programs.
• Effective date: This inclusion will take effect on March 9, 2026.
• Trading opportunity: From the effective date, eligible mainland Chinese investors who meet admission criteria will be able to trade the Company’s H shares listed on The Stock Exchange of Hong Kong via the Stock Connect mechanisms.
• Potential impact: The Board expects that this inclusion will help to expand the shareholder base and increase the trading liquidity of the Company’s H shares.

Why Is This Important for Shareholders?

• Broader investor base: Inclusion in both Stock Connect programs enables qualified mainland investors to access CF PharmTech’s H shares, potentially boosting demand and trading volume.
• Enhanced liquidity: Increased trading activity can narrow bid-ask spreads and support more efficient price discovery for the Company’s shares.
• Potential for re-rating: As the Company becomes more accessible to a broader pool of institutional and retail investors, there could be a re-rating of the share price to reflect the new demand dynamics.
• Market visibility: Being part of the Stock Connect programs enhances the Company’s profile among mainland investors and may attract greater analyst coverage and institutional interest.

Company Overview and Strategic Developments

CF PharmTech, Inc. is recognized as a global innovator in inhalation drug delivery technology. The Company stands out as a specialist in developing complex inhalation formulations with high barriers to entry, and operates as a platform-based pharmaceutical enterprise with integrated capabilities across device engineering, precision drug delivery, global regulatory filing, and commercialization.

The Company boasts end-to-end, self-developed capabilities, including exhalation-powered nasal spray delivery systems, liposomal inhalation technology, and siRNA nucleic acid delivery platforms. Its proprietary innovation pipeline is advancing in major markets such as China, the United States, and Europe.

• Therapeutic focus: Respiratory diseases (asthma, COPD, bronchiectasis), nasal diseases (allergic rhinitis, chronic rhinosinusitis), and strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections, and CNS disorders via nose-to-brain precision delivery.
• Commercial network: The Company has established an extensive multi-dimensional commercialization network in China and is steadily advancing its international presence through globally compliant manufacturing systems.

These strategic moves reinforce CF PharmTech’s ambition to become a global innovative pharmaceutical enterprise.

Leadership and Governance

The Board of Directors is chaired by Dr. LIANG Bill Wenqing, who also serves as Executive Director and CEO. The Board comprises a mix of executive, non-executive, and independent non-executive directors, reflecting a strong governance structure.

Important Considerations for Investors

• Potential share price catalyst: The inclusion in the Stock Connect programs is a significant, potentially price-sensitive event that may positively impact the valuation and liquidity of CF PharmTech’s H shares.
• Caution advised: The Company has advised shareholders and potential investors to exercise caution when dealing in its securities, as the share price may react to these developments.

Disclaimer: The above article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. The Company’s share price may be subject to volatility and other risks associated with market developments.

View CF PHARMTECH Historical chart here